GB Sciences (GBLX) 10-Q 14 Aug 14 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Jun. 30, 2014	Aug. 12, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'Growblox Sciences, Inc.	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Entity Central Index Key	'0001165320	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	32,473,282
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'

Consolidated_Condensed_Balance

Consolidated Condensed Balance Sheets (USD $)	Jun. 30, 2014	Mar. 31, 2014
Current assets:	'	'
Cash	$3,213,358	$339,327
Subscription Receivable	'	150,000
Inventory	3,000	'
Prepaid expenses and other current assets	17,664	'
Total current assets	3,234,022	489,327
Property and Equipment:	'	'
Property and Equipment, net	74,021	44,922
Intangible assets, net	3,675	3,735
Total property and equipment	77,696	48,657
Total assets	3,311,718	537,984
Current liabilities:	'	'
Accounts payable	33,862	19,762
Subscription payable	35,250	10,000
Accrued interest	108,749	252,304
Other accrued expenses	1,847	1,847
Notes from shareholders	5,000	5,000
Convertible notes from shareholders	368,610	1,262,441
Total current liabilities	553,318	1,551,354
Commitments and contingencies	'	'
Stockholders' equity (deficiency):	'	'
Common stock, $0.0001 par value, 250,000,000 shares authorized 32,473,282 and 7,268,948 shares issued and outstanding at June 30, 2014 and March 31, 2014	3,247	727
Additional paid-in capital	10,350,432	5,198,659
Accumulated deficit	-7,657,974	-6,212,756
Total stockholders' equity (deficiency)	2,695,705	-1,013,370
Noncontrolling interest	62,695	'
Total equity	2,758,400	-1,013,370
Total liabilities and stockholders' equity (deficiency)	$3,311,718	$537,984

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Mar. 31, 2014
Statement of Financial Position	'	'
Common stock, par or stated value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	32,473,282	7,268,948
Common Stock, shares outstanding	32,473,282	7,268,948

Consolidated_Condensed_Stateme

Consolidated Condensed Statements of Operations (unaudited) (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Statement	'	'
Net revenue	'	'
Cost of revenue	'	'
Gross profit (loss)	'	'
Stock compensation	537,296	0
Investor relations	396,000	0
General and administrative expenses	561,900	29,487
Loss from continuing operations	-1,495,196	-29,487
Other income/(expense)	'	'
Interest expense	0	-12,717
Interest income	173	0
Total other income/(expenses)	173	-12,717
Total income/(loss)	-1,495,023	-42,204
Less net income (loss) attributable to noncontrolling interests	-49,805	0
Net income/(loss)	($1,445,218)	($42,204)
Weighted average common shares outstanding:	'	'
Basic and diluted	3,658,004	850,110
Net income/(loss) per share	'	'
Basic and diluted	($0.40)	($0.05)

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($1,445,218)	($42,204)
Less net loss attributable to noncontrolling interest	-49,805	0
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation expense	227	75
Amortization expense	60	'
Stock compensation	537,296	'
Non-cash interest	'	1,694
Changes in operating assets and liabilities:	'	'
Inventory	-3,000	'
Prepaid expenses	-13,564	'
Other assets	-4,100	'
Accounts payable	14,100	10,825
Stock subscription payable	25,250	'
Accrued expenses	'	18,705
Net cash used in operating activities	-938,754	-10,905
Cash flows from investing activities:	'	'
Purchase of property and equipment	-29,326	'
Net cash used in investing activities	-29,326	'
Cash flows from financing activities:	'	'
Stock subscription receivable	150,000	'
Proceeds from issuance of stock	3,579,612	'
Proceeds from noncontrolling interest	112,500	'
Proceeds from issuance of debt to stockholders	'	26,000
Net cash provided by financing activities	3,842,112	26,000
Net increase (decrease) in cash	2,874,032	15,095
Cash, beginning of year	339,327	2,427
Cash, end of June 30, 2014	3,213,359	17,522
Supplemental disclosures of cash flow information:	'	'
Cash paid during the year for: Interest	'	'
Non-cash investing and financing activities:	'	'
Stock issued to settle convertible debt	893,831	'
Stock issued to settle interest expense	$143,555	'

Note_1_Organization_and_Princi

Note 1 - Organization and Principles of Consolidation	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 1 - Organization and Principles of Consolidation	'
	NOTE 1 - ORGANIZATION AND PRINCIPLES OF CONSOLIDATION
	The accompanying unaudited condensed financial statements have been prepared by the Company, pursuant to the rules and regulations of the U. S. Securities and Exchange Commission for Form 10-Q.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.  The unaudited condensed financial statements included herein reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim period.  Interim results are not necessarily indicative of the results that may be expected for the year.  The unaudited condensed financial statements should be read in conjunction with the condensed financial statements and notes thereto, together with management’s discussion and analysis of financial condition and results of operation, for the year ended March 31, 2014, contained in the Company’s March 31, 2014 Annual Report on Form 10-K.
	The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced net losses since April 4, 2001 which losses have caused an accumulated deficit of approximately $7,600,000 as of June 30, 2014. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
	Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing.  There are no assurances that the Company will be successful in achieving its goals.
	In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. The Company is currently in the process of acquiring and developing crude oil and natural gas leases. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company cannot continue as a going concern.

Note_2_Basis_of_Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 2 - Basis of Presentation	'
	NOTE 2 – BASIS OF PRESENTATION
	Reporting Entity. GrowBlox Sciences, Inc.  (“GrowBlox” or “the Company”) was incorporated on April 4, 2001 under the laws of the State of Delaware. The Company is authorized to issue 250,000,000 shares of common stock, par value $.0001. On March 18, 2014, we purchased assets from Craig Ellins, which included the revolutionary GrowBLOX technology. We plan to utilize this technology to commercially cultivate and produce medical grade cannabis for sale in the U.S. states and territories in which it is legal. We also plan to research the medical treatment potential of cannabis and develop treatments from those findings. On April 4, 2014, we officially changed our name to GrowBLOX Sciences, Inc. to reflect this new corporate direction.  The Company’s office is located in Las Vegas, Nevada.

Note_3_Summary_of_Significant_

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 3 - Summary of Significant Accounting Policies	'
	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Development Stage Company. The Company is considered to be in the development stage.
	Cash and Cash Equivalents. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
	Property and Equipment. Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3-8 years for machinery and equipment, leasehold improvements are amortized over the shorter of the estimated useful lives or the underlying lease term. Repairs and maintenance expenditures which do not extend the useful lives of related assets are expensed as incurred.
	Income Taxes.  The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.   Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% of the related deferred tax assets.
	Loss per Share. The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company has 8,757,106 potentially dilutive common shares at March 31, 2014.  However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.
	Fair Value Measurement. ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).  ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability. The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:
	Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.
	Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
	Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 fair value elections are made on an instrument by instrument basis.
	In accordance with the fair value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. The Company has not elected the fair value option for any eligible financial instruments.
	Recent Accounting Pronouncements
	There were no recently issued accounting pronouncements that will have a material impact on the Company’s financial statements

Note_4_Convertible_Notes_and_W

Note 4 - Convertible Notes and Warrants	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 4 - Convertible Notes and Warrants	'
	NOTE 4 – CONVERTIBLE NOTES AND WARRANTS
	Convertible Notes from Shareholders
	The Company has debt outstanding to shareholders, which was issued between 2006 and 2013. The debt was not issued with warrants and some of the debt was not originally issued with a conversion feature. During fiscal years 2009 and 2010, the notes without conversion features were modified to contain a conversion feature, for which the Company recorded a loss on the modification.  Convertible notes from shareholders issued during fiscal year 2010 contained a beneficial conversion feature, with the discount being amortized over the term of the note.
	Convertible notes from shareholders accrued interest at a rate of 10 percent per annum. The note holders had the sole option of converting the principal and interest represented by these notes into our common stock at a strike price equal to a $0.01. The note holders were only be allowed to convert shares or portion thereof to the extent that, at the time of the conversion, the conversion will not result in the note holders beneficially owning more than 9.9% of the issued and outstanding common shares of the Company.
	Additional, between December, 2009 and February, 2013, the Company entered into several Convertible Note Agreements ("Notes") for a total of $1,033,744.  The Company received aggregate proceeds of $884,700 reflecting a 15% original issue discount to the Note holders and a nominal rate of 16.63%.
	The Notes were due after one year.  The note holders could have converted any portion of the Notes that are outstanding, whether such portion represents principal or interest, into shares of common stock of the Company at a price equal to $0.10. The Notes includes an anti-dilution adjustment that may not be adjusted below $0.01.
	Simultaneously with the issuance of these Notes, the Company issued to the Note holders a 5-year warrant (the "Warrants") to purchase 12,364,766 shares of common stock of the Company.  The Warrants were exercisable at a price equal to $0.15. The Warrants included an anti-dilution adjustment that may not be adjusted below $0.01.
	The note holders were only be allowed to convert shares or exercise warrants or portion thereof to the extent that, at the time of the conversion or exercise, the conversion or exercise will not result in the note holder beneficially owning more than 9.9% of the issued and outstanding common shares of the Company.
	Simu ltaneously with the issuance of this Note, the Company issued to each Note holder a 5-year warrant (the "Warrant") to purchase 504,203 shares of common stock of the Company.  The Warrant is exercisable at a price equal to $0.50. The Warrants include an anti-dilution adjustment that may not be adjusted below $0.01.
	The note holder will only be allowed to convert shares or exercise warrants or portion thereof to the extent that, at the time of the conversion or exercise, the conversion or exercise will not result in the note holder beneficially owning more than 9.9% of the issued and outstanding common shares of the Company.
	In March 2014, the note holders’ agreed to modify the terms of all the notes and warrants.  The notes are now convertible at a fixed price of $0.26.  The warrants have been cancelled and no longer have any value.  A loss of $559,048 for the extinguishment of debt has been recorded on the State of Operations as of March 31, 2014.
		For the three months ended June 30, 2014		For the year ended March 31, 2014
		Convertible Notes	Accrued Interest	Convertible Notes	Accrued Interest
	Balance, beginning of period	$1,262,441	$252,304	$1,376,228	$208,088
	Conversion to common stock	893,831	252,304	114,057	-
	Accrued interest	-	-	-	44,216
	Balance, end of period	$368,610	$108,749	$1,262,441	$252,304
		Warrants Outstanding
		Number of Shares	Exercise Price
	Outstanding at March 31, 2013	12,364,766	0.15-$0.10
	Warrants issued	2,960,000	1.00-$2.00
	Warrants exercised	-	-
	Warrants expired/cancelled	-12,364,766	-
	Outstanding at March 31, 2014	2,960,000	1.00-$2.00
	Warrants issued	12,038,446	0.55-$2.00
	Warrants exercised	-	-
	Warrants expired/cancelled	-	-
	Outstanding at June 30, 2014	14,995,446	0.55-$2.00

Note_5_Stockholders_Equity_cap

Note 5 - Stockholders' Equity (capital Deficiency)	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 5 - Stockholders' Equity (capital Deficiency)	'
	NOTE 5 – STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)
	From April 2014 to June 2014, the Company converted a total of $1,015,459 of notes payable from certain Note Holders into common stock of the Company.  The Company issued 3,905,612 shares of our common stock to satisfy the principal and interest balances of the notes payable.
	As of June 30, 2014, the Company sold 4,520,000 units through a private placement.   Each unit consists of one share of common stock, one A warrant, expiring in three years, with an exercise price of $1.00 and one B warrant, expiring in five years, with an exercise price of $2.00. The price was $0.50 per unit.
	On March 13, 2014 the Company entered into a definitive agreement (the “Agreement”) with Mr. Craig Ellins for the acquisition of assets.  In accordance with the Agreement, Mr. Ellins was issued an additional four million shares upon the completion of a minimum of $1,000,000 in proceeds to the Company from fund raising on May 1, 2014.  The shares were issued pursuant to the exemption from registration set forth in Section 4(2) of the Securities Act of 1933.
	On June 27, 2014, the Company issued 8,950,000 shares of common stock pursuant to the employment contracts of our three executive officers valued at $1.24 per share.   Fifty thousand of the shares were paid directly to one of the officers.  The remaining shares will be held by the Company until such time as certain milestones are reached and vesting periods have run.  The issuance was exempt from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the Act because there was no public offering in connection with the issuance of the shares.

Note_6_Subsequent_Events

Note 6 - Subsequent Events	3 Months Ended
	Jun. 30, 2014
Notes	'
Note 6 - Subsequent Events	'
	NOTE 6 – SUBSEQUENT EVENTS
	On July 15, 2014 the Company converted a total of $307,356 of notes payable from certain Note Holders into common stock of the Company.  The Company issued 1,202,500 shares of our common stock to satisfy the principal and interest balances of the notes payable.

Note_3_Summary_of_Significant_1

Note 3 - Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2014
Policies	'
Development Stage Company	'
	Development Stage Company. The Company is considered to be in the development stage.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
Property, Plant and Equipment	'
	Property and Equipment. Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3-8 years for machinery and equipment, leasehold improvements are amortized over the shorter of the estimated useful lives or the underlying lease term. Repairs and maintenance expenditures which do not extend the useful lives of related assets are expensed as incurred.
Income Taxes	'
	Income Taxes.  The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.   Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% of the related deferred tax assets.
Loss Per Share	'
	Loss per Share. The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company has 8,757,106 potentially dilutive common shares at March 31, 2014.  However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.
Fair Value Measurement	'
	Fair Value Measurement. ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).  ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability. The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:
	Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.
	Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
	Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 fair value elections are made on an instrument by instrument basis.
	In accordance with the fair value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. The Company has not elected the fair value option for any eligible financial instruments.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were no recently issued accounting pronouncements that will have a material impact on the Company’s financial statements

Note_4_Convertible_Notes_and_W1

Note 4 - Convertible Notes and Warrants (Tables)	3 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Convertible Debt	'
		For the three months ended June 30, 2014		For the year ended March 31, 2014
		Convertible Notes	Accrued Interest	Convertible Notes	Accrued Interest
	Balance, beginning of period	$1,262,441	$252,304	$1,376,228	$208,088
	Conversion to common stock	893,831	252,304	114,057	-
	Accrued interest	-	-	-	44,216
	Balance, end of period	$368,610	$108,749	$1,262,441	$252,304
Schedule of Warrant Activity	'
		Warrants Outstanding
		Number of Shares	Exercise Price
	Outstanding at March 31, 2013	12,364,766	0.15-$0.10
	Warrants issued	2,960,000	1.00-$2.00
	Warrants exercised	-	-
	Warrants expired/cancelled	-12,364,766	-
	Outstanding at March 31, 2014	2,960,000	1.00-$2.00
	Warrants issued	12,038,446	0.55-$2.00
	Warrants exercised	-	-
	Warrants expired/cancelled	-	-
	Outstanding at June 30, 2014	14,995,446	0.55-$2.00

Note_1_Organization_and_Princi1

Note 1 - Organization and Principles of Consolidation (Details) (USD $)	Jun. 30, 2014	Mar. 31, 2014
Details	'	'
Accumulated deficit	($7,657,974)	($6,212,756)

Note_2_Basis_of_Presentation_D

Note 2 - Basis of Presentation (Details) (USD $)	Jun. 30, 2014	Mar. 31, 2014
Details	'	'
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par or stated value	$0.00	$0.00

Note_3_Summary_of_Significant_2

Note 3 - Summary of Significant Accounting Policies: Loss Per Share (Details) (Common stock)	3 Months Ended
	Mar. 31, 2014
Common stock	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,757,106

Note_4_Convertible_Notes_and_W2

Note 4 - Convertible Notes and Warrants (Details) (USD $)	3 Months Ended	12 Months Ended	39 Months Ended				3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Feb. 28, 2013	Feb. 28, 2013	Feb. 28, 2013	Feb. 28, 2013	Jun. 30, 2014	Mar. 31, 2014
				Warrant	Warrant 2	Convertible Note Agreements	Convertible Notes	Convertible Notes
Convertible notes from shareholders accrued interest rate	'	'	'	'	'	'	10.00%	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	'	$0.10	$0.01	$0.26
Debt Instrument, Convertible, Terms of Conversion Feature	'	'	'	'	'	'	'The note holders were only be allowed to convert shares or portion thereof to the extent that, at the time of the conversion, the conversion will not result in the note holders beneficially owning more than 9.9% of the issued and outstanding common shares of the Company.	'
Debt Instrument, Face Amount	'	'	'	'	'	$1,033,744	'	'
Proceeds from Convertible Debt	'	'	884,700	'	'	'	'	'
Original Issuance Discount	15.00%	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	16.63%	'	'	'	'	'	'	'
Debt Instrument, Maturity Date, Description	'	'	'	'	'	'The Notes were due after one year.	'	'
Anti-dilution adjustment	'	'	'	$0.01	$0.01	$0.01	'	'
Warrants, Issued	12,038,446	2,960,000	'	12,364,766	504,203	'	'	'
Warrants, Exercise Price	'	'	'	$0.15	$0.50	'	'	'
Loss on extinguishment of debt	'	'	'	'	'	'	'	($559,048)

Note_4_Convertible_Notes_and_W3

Note 4 - Convertible Notes and Warrants: Convertible Debt (Details) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Mar. 31, 2013
Details	'	'	'
Convertible notes from shareholders	$368,610	$1,262,441	$1,376,228
Accrued interest	108,749	252,304	208,088
Conversion to common stock, Convertible Notes	893,831	114,057	'
Conversion to common stock, Accrued Interest	252,304	'	'
Increase (Decrease) in Accrued Interest	'	$44,216	'

Note_4_Convertible_Notes_and_W4

Note 4 - Convertible Notes and Warrants: Schedule of Warrant Activity (Details) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Mar. 31, 2013
Warrants, Outstanding	14,995,446	2,960,000	12,364,766
Warrants, Issued	12,038,446	2,960,000	'
Warrants, Exercised	0	0	'
Warrants, Exercised, Weighted Average Exercise Price	$0	$0	'
Warrants, Expired	0	-12,364,766	'
Warrants, Expirations, Weighted Average Exercise Price	$0	$0	'
Minimum	'	'	'
Warrants, Weighted Average Exercise Price	$0.55	$1	0.15
Warrants, Granted, Weighted Average Exercise Price	$0.55	$1	'
Maximum	'	'	'
Warrants, Weighted Average Exercise Price	$2	$2	0.1
Warrants, Granted, Weighted Average Exercise Price	$2	$2	'

Note_5_Stockholders_Equity_cap1

Note 5 - Stockholders' Equity (capital Deficiency) (Details) (USD $)	3 Months Ended
	Jun. 30, 2014
Common stock	'
Issuance of stock to satisfy principal and interest balances of notes payable	3,905,612
Common stock | Craig Ellins	'
Stock Issued During Period, Shares, Acquisitions	4,000,000
Stock Issued During Period, Description	'upon the completion of a minimum of $1,000,000 in proceeds to the Company from fund raising on May 1, 2014. The shares were issued pursuant to the exemption from registration set forth in Section 4(2) of the Securities Act of 1933.
Common stock | Three Executive Officers	'
Equity Issuance Price	1.24
Issuance of stock pursuant to employment contracts	8,950,000
Issuance of stock pursuant to employment contracts, description	'Fifty thousand of the shares were paid directly to one of the officers. The remaining shares will be held by the Company until such time as certain milestones are reached and vesting periods have run. The issuance was exempt from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the Act because there was no public offering in connection with the issuance of the shares.
Capital Units	'
Stock sold through private placement	4,520,000
Equity Issuance Price	0.5
A Warrant	'
Warrants, Exercise Price	1
B Warrant	'
Warrants, Exercise Price	2
Notes payable	'
Converted notes payable from certain Note Holders into common stock	1,015,459

Note_6_Subsequent_Events_Detai

Note 6 - Subsequent Events (Details) (USD $)	3 Months Ended		1 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jul. 31, 2014	Jul. 31, 2014
	Common stock	Notes payable	Subsequent Event	Subsequent Event
			Common stock	Notes payable
Converted notes payable from certain Note Holders into common stock	'	$1,015,459	'	$307,356
Issuance of stock to satisfy principal and interest balances of notes payable	3,905,612	'	1,202,500	'